Clinical Characteristics of Rheumatoid Arthritis Patients in Malang: Where Are We Now According to the Treat-to-Target Strategy?

Background: Rheumatoid arthritis (RA) is the most frequent type of systemic inflammatory arthritis. Aim: to observe RA patients' clinical characteristics in Malang and assess the adherence of the clinical data to the existing guideline for the treat-to-target (T2T) strategy. Methods: This...

Full description

Bibliographic Details
Published in:	Clinical and Research Journal in Internal Medicine
Main Authors:	Mirza Zaka Pratama, Bagus Suryana, Nurhandi Megawanto
Format:	Article
Language:	English
Published:	Universitas Brawijaya 2023-11-01
Subjects:	rheumatoid arthritis disease remission clinical characteristics treat to target
Online Access:	https://crjim.ub.ac.id/index.php/crjim/article/view/184

Similar Items

Difficult-to-treat rheumatoid arthritis. What is it?
by: A. V. Gordeev, et al.
Published: (2021-10-01)

RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE
by: E. L. Nasonov, et al.
Published: (2018-07-01)

Are the goals of therapy achievable in patients with rheumatoid arthritis receiving upadacitinib in real clinical practice?
by: V. N. Amirjanova, et al.
Published: (2022-07-01)

ADALIMUMAB DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING SUSTAINED REMISSION
by: N. V. Demidova, et al.
Published: (2018-07-01)

Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?
by: Serena Bugatti, et al.
Published: (2018-05-01)

Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
by: Laura M. M. Steunebrink, et al.
Published: (2018-01-01)

Characteristics of difficult-to-treat rheumatoid arthritis: a real-life study
by: C. Charoui, et al.
Published: (2024-07-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: RUSSIAN AND INTERNATIONAL GUIDELINES
by: E. L. Nasonov
Published: (2016-12-01)

The Clinical Value of Autoantibodies in Rheumatoid Arthritis
by: Serena Bugatti, et al.
Published: (2018-12-01)

Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender
by: Nicoletta Luciano, et al.
Published: (2025-01-01)

Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis
by: GF Ferraccioli, et al.
Published: (2011-05-01)

Treating rheumatoid arthritis to target: Russian version of international guidelines for patients
by: Evgenia Vladislavovna Orlova, et al.
Published: (2013-06-01)

Prognostic evaluation of early rheumatoid arthritis
by: Mota da, et al.
Published: (2010-09-01)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
by: Noriko Kimura, et al.
Published: (2019-03-01)

Optical imaging (HandScan) can identify ultrasound remission in rheumatoid arthritis
by: Charline Rinkin, et al.
Published: (2024-05-01)

Cytokine Signatures as Biomarkers of Clinical Remission in Rheumatoid Arthritis
by: Su W, et al.
Published: (2025-06-01)

Intensive therapy and remissions in rheumatoid arthritis: a systematic review
by: Catherine D. Hughes, et al.
Published: (2018-10-01)

Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
by: Eugen Feist, et al.
Published: (2022-02-01)

Establishing Rheumatoid Arthritis Care in Zanzibar: A Year of Clinical Outcomes and Challenges
by: Sanaa Said, et al.
Published: (2025-03-01)

The long-term remission of rheumatoid arthritis with a single cycle of rituximab
by: Glišić Branislava, et al.
Published: (2012-01-01)

Experience with tocilizumab in patients with rheumatoid arthritis (according to the data of the LORNET multicenter trial)
by: E Yu Panasyuk, et al.
Published: (2013-04-01)

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
by: José A. Sacristán, et al.
Published: (2019-10-01)

The application value of MRI in the diagnosis of subclinical inflammation in patients with rheumatoid arthritis in remission
by: Huimei Zhang, et al.
Published: (2018-07-01)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
by: Tanja Alexandra Stamm, et al.
Published: (2018-08-01)

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis
by: Marina G. Birck, et al.
Published: (2025-07-01)

Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: a cohort study
by: Rudy Hidayat, et al.
Published: (2024-09-01)

Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat
by: Bernardo D’Onofrio, et al.
Published: (2024-11-01)

The use of hepcidin as a marker for diagnosing the type of anemia in patients with high activity of rheumatoid arthritis
by: A. S. Semashko, et al.
Published: (2023-12-01)

Transitional and CD21− PD-1+ B cells are associated with remission in early rheumatoid arthritis
by: Sarah McGrath, et al.
Published: (2025-04-01)

Sustained remission of rheumatoid arthritis following COVID-19 vaccination
by: Angelo Nigro
Published: (2025-06-01)

AN ECONOMIC PRICE ANALYSIS OF CONVENTIONAL REMISSION THERAPY VS BIOLOGICAL THERAPY FOR RHEUMATOID ARTHRITIS TREATMENT
by: Mihaela-Simona SUBTIRELU, et al.
Published: (2019-05-01)

Egyptian guidelines for the treatment of Rheumatoid Arthritis — 2022 update
by: Yasser El Miedany, et al.
Published: (2022-10-01)

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study
by: Peter C. Taylor, et al.
Published: (2024-12-01)

Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort
by: Stéphanie Dierckx, et al.
Published: (2020-04-01)

THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS
by: D. E. Karateev, et al.
Published: (2014-12-01)

THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS
by: D. E. Karateev, et al.
Published: (2015-10-01)

THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS
by: D. E. Karatee, et al.
Published: (2016-12-01)

Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
by: Ju-Yang Jung, et al.
Published: (2023-09-01)

LONG-TERM OUTCOMES IN RHEUMATOID ARTHRITIS IN RELATION TO THE TIME AFTER THE INITIATIONOF BASIC ANTI-INFLAMMATORY DRUG THERAPY
by: Natalya Vladimirovna Chichasova, et al.
Published: (2010-06-01)

ASSOCIATION BETWEEN CLINICAL MANIFESTATIONS AND ULTRASONIC SIGNS OF INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: O. G. Alekseeva, et al.
Published: (2016-02-01)